STOCK MARKET BSE NSE

National Task Force, JMG will decide on continuing plasma therapy for treatment of COVID patients: ICMR

ICMR Director General Dr Balram Bhargava said that plasma therapy has been used for more than 100 years now in some form or the other for various virus infections.

Published: 15th September 2020 09:04 PM  |   Last Updated: 16th September 2020 02:24 AM   |  A+A-

A COVID-19 survivor donates plasma at a Plasma Bank

A COVID-19 survivor donates plasma at a Plasma Bank. (Photo | PTI)

By PTI

NEW DELHI: The National Task Force on COVID-19 and the joint monitoring group (JMG) in the Health Ministry will take a decision on whether to continue plasma therapy in the treatment of COVID-19 patients in India after reviewing the data of its randomised controlled trial, the ICMR said on Tuesday.

Addressing a press conference, ICMR Director General Dr Balram Bhargava said a randomised controlled trial, including 464 patients in 39 hospitals in 25 districts across 14 states and UTs, has shown that plasma therapy does not reduce mortality or prevent progression from moderate to severe disease.

He said that plasma therapy has been used for more than 100 years now in some form or the other for various virus infections.

It was used during ebola and it was also being used amid the COVID-19 pandemic.

ALSO READ | Over 38.5 lakh COVID patients have recovered; one of the highest number of recoveries globally: Government

"Having said that whether it benefits or not is being studied," the ICMR director general said.

Referring to the findings of the ICMR funded randomised controlled trial, Bhargava said this a pre-print version which is still undergoing peer review.

"Once peer review happens and we get full publication out, this data will be considered again by the National Task Force and joint monitoring group of the Health Ministry and then a decision will be taken if we should continue with this or not because at the moment we have got permission to use plasma therapy (off label) in India," he said.

"There are a few cases where some reactions can occur and therefore, we will take a considered view once we get the full publication of this study," he underlined.

The Clinical Management Protocols for COVID-19 issued by the Union Health Ministry on June 27 allowed use of convalescent plasma (off label) for treating coronavirus-infected patients in moderate stage of the illness under "investigational therapies".

More from Nation.

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

IPL_2020
flipboard facebook twitter whatsapp